You are here: Industry Insights > NIH

News List

Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial prnewswire
June 30, 2021
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that fostamatinib, the Company's novel oral spleen tyrosine kinase (SYK) inhibitor, has been selected for a National Institutes of Health ACTIV-4 trial in hospitalized patients with COVID-19.
Fox Chase Researcher Receives NIH Grant to Advance Treatment of Immune Diseases Using Genome Editing firstwordpharma
June 29, 2021
A Fox Chase Cancer Center researcher has received a grant of approximately half a million dollars from the National Institutes of Health (NIH) to identify disease-causing T cell defects.
NIH Awards Vibrent Health Contract to Create a New Paradigm for Pandemic Preparedness and Response americanpharmaceuticalreview
June 17, 2021
The National Institutes of Health’s (NIH) National Cancer Institute (NCI) has awarded Vibrent Health, a digital health technology company powering the future of precision health research, the second phase of a contract to validate COVID-CARE ...
NIH researchers identify potential new antiviral drug for COVID-19 worldpharmanews
June 07, 2021
The experimental drug TEMPOL may be a promising oral antiviral treatment for COVID-19, suggests a study of cell cultures by researchers at the National Institutes of Health.
NIH Starts Trial Assessing 'Mix & Match' COVID-19 Vaccine Approach drugs
June 03, 2021
There is a new clinical trial underway to assess the safety and effectiveness of mixing different types of booster shots in adults who have been fully vaccinated against COVID-19.
NIH trial to add Trevena’s TRV027 for Covid-19 treatment pharmaceutical-technology
May 08, 2021
TRV027 is an angiotensin II receptor type 1 (AT1 receptor) selective agonist and fights disruption within the renin-angiotensin-aldosterone system (RAAS) by attaching to and rebalancing AT1 receptor activation.
NIH scientists identify small-molecule cocktail to prevent cellular stress pharmaceutical-technology
May 06, 2021
The US National Institutes of Health (NIH) scientists have identified a four-part small-molecule cocktail that can provide protection to induced pluripotent stem cells (iPSCs) from stress and preserve regular stem cell structure and function.
FDA Takes Action for Failure to Submit Required Clinical Trials Results to Clinicaltrials.gov americanpharmaceuticalreview
April 30, 2021
The FDA has issued its first Notice of Noncompliance to Acceleron Pharma, Inc. (Acceleron) for failing to submit required summary results information to ClinicalTrials.gov.
NIH trial to evaluate antibody therapy for Covid-19 treatment pharmaceutical-technology
April 23, 2021
The National Institutes of Health (NIH) has commenced subject enrolment in a Phase II/III ACTIV-2 trial of a new fully human polyclonal antibody therapeutic called SAB-185 for treating Covid-19 in non-hospitalised individuals with mild or moderate ...
NIH-funded trial to assess repurposed drugs for Covid-19 treatment pharmaceutical-technology
April 21, 2021
The National Institutes of Health (NIH) is set to fund the Phase III ACTIV-6 clinical trial to analyse various prescription and over-the-counter medications that are currently available for self-administration to treat Covid-19 symptoms.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page